Download the free Cancer Therapy Advisor app now!
The Cancer Therapy Advisor app is a free, easy-to-use app that offers oncology professionals the latest in oncology news and emerging trends, as well as cancer treatment regimens, full-length features, slideshows, case studies, and drug information for a variety of cancer types and therapeutic areas.
Download Cancer Therapy Advisor for free and access us on the go! Register for CTA directly from your device or log in using your existing account details.
What you'll find on the Cancer Therapy Advisor app
Our popular Viewpoint features discuss the latest developments by your colleagues.
Supplemental courses of treatment for various types of cancers including dosing, administration and management of related adverse events.
Hundreds of oncology-specific accredited courses from our partners at the myCME education library. Claim your certificate instantly!
Our calculators can assess liver function, convert HbA1C to mean plasma glucose, evaluate BP, determine BMI and more, at the point-of-care.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified